#B16171 variant is 6.8-fold less susceptible to neutralization by sera from infection & vaccinated (Pfizer & Moderna) subjects. Despite this, most of the sera from convalescents (79%) & all from vaccinated subjects were still able to neutralize the variant biorxiv.org/content/10.110… 
#Covaxin retains efficacy against #B1617: Only minimal reductions in the neutralization observed against B1617; Neutralization reduction by a factor of 1.95 & 1.8 was observed against the B1617 variant for B1 (D614G) & B117 variant, respectively. biorxiv.org/content/10.110…
#B16171 variant is highly pathogenic in hamsters than B1 (D614G) variant! B1617 demonstrates higher pathogenicity evident with reduced body weight, higher viral load in lungs & pronounced lung lesions as compared to B1 biorxiv.org/content/10.110…
Potential impacts of #B1617 variant on Vaccine Effectiveness or therapeutics, or reinfection risks, remain uncertain. However, it is highly transmissible. Lab studies suggest a limited reduction in neutralization by antibodies; however, real-world impacts may be limited
• • •
Missing some Tweet in this thread? You can try to
force a refresh
